Drug · DIN 02370050
BENLYSTA
FOR I.V. INFUSION ONLY. 80MG/ML(RECONST.) - 5ML VIAL.
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 24, 2011; first marketed August 24, 2011.
- Drug Identification Number (DIN)
- 02370050
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Belimumab L04AG04
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BELIMUMAB | 120 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 6, 2011: NOC 12482New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “benlysta”. A notice may cover another product or only some lots: read it to see what it covers.
- BENLYSTA (belimumab) - Progressive Multifocal Leukoencephalopathy Reported in Patients - For Health ProfessionalsApril 28, 2014 · Biologic or vaccine · Product safety
- BENLYSTA (belimumab) - Progressive Multifocal Leukoencephalopathy Reported in Patients - For the PublicApril 28, 2014 · Biologic or vaccine · Product safety
- BENLYSTA (belimumab) – Association with Hypersensitivity and Infusion Reactions – For the PublicMay 8, 2012 · Drugs · Product safety
- Benlysta (belimumab) - Association with Hypersensitivity and Infusion Reactions - For Health ProfessionalsMay 8, 2012 · Biologic or vaccine
Other DINs named BENLYSTA
- DIN 02370069 · Marketed
- DIN 02470489 · Marketed
- DIN 02470470 · Cancelled Pre Market